Search results
Results from the WOW.Com Content Network
There is evidence from systematic review and meta-analyses that statins, particularly atorvastatin, reduce both decline in kidney function (eGFR) and the severity of protein excretion in urine, [30] [31] [32] with higher doses having greater effect. [31] [32] Data are conflicting for whether statins reduce risk of kidney failure. [30]
Statins and heart disease in brief. ... such as kidney and metabolic function and statin use. Also, it no longer includes race. ... Patients who may be taken off the drugs could be confused and ...
Researchers tested simvastatin, later sold by Merck as Zocor, on 4,444 patients with high cholesterol and heart disease. After five years, the study concluded the patients saw a 35% reduction in their cholesterol, and their chances of dying of a heart attack were reduced by 42%.
The main components of managing cardiovascular disease is with tobacco cessation, lipid-lowering therapies (e.g., statins) as well as regular exercise and healthy eating. [36] In patients with kidney disease, atorvastatin is preferred over other statins as it does not require dose-adjustment based on GFR. [37]
It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.
Impact of statins on cholesterol, heart disease risk Cheng-Han Chen, MD , of Saddleback Medical Center, CA, not involved in the study, explained that cholesterol in the body comes from two sources.
Ezetimibe inhibits the intestinal absorption of cholesterol and can be used alone or with statins. [24] Regarding cardiovascular events, patients with chronic kidney disease saw a reduction in vascular and major atherosclerotic events when on simvastatin and ezetimibe compared to placebo. [25]
A 2010 published meta-analysis found for every 255 patients taking a statin for 4 years, one additional case of diabetes would occur whilst preventing 5.4 major coronary events. [27] Some drugs interact with statins in a way that increases the risk of muscle injury called myopathy, characterized by unexplained muscle weakness or pain.